Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections.
Open accessThe DOI matches its Crossref record; 695 of the 697 references it cites were found in a registry or an index.
Abstract
Background: The Infectious Diseases Society of America is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase–producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia. This updated document replaces previous versions of the guidance document. Methods: A panel of 6 infectious diseases specialists with expertise in managing antimicrobial-resistant infections formulated questions about the treatment of infections caused by extended-spectrum β-lactamase-producing Enterobacterales, AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Enterobacterales, Pseudomonas aeruginosa with difficult-to-treat resistance, carbapenem-resistant Acinetobacter baumannii, and S. maltophilia. Because of differences in the epidemiology of resistance and availability of specific anti-infectives internationally, this document focuses on the treatment of infections in the United States. Results: Preferred and alternative suggested treatment approaches are provided with accompanying rationales, assuming the causative organism has been identified and antibiotic susceptibility results are known. Approaches to empiric treatment, transitioning to oral therapy, duration of therapy, and other management considerations are also discussed briefly. Suggested approaches apply for both adult and pediatric populations, although suggested antibiotic dosages are provided only for adults. Conclusions: The field of antimicrobial-resistance is highly dynamic. Consultation with an infectious diseases specialist is recommended for the treatment of antimicrobial resistant infections. This document is current as of 31 December 2022 and will be updated periodically. The most current version of this document, including date of publication, is available at www.idsociety.org/practice-guideline/amr-guidance/.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316
Magiorakos, A.-P., Srinivasan, A., Carey, R. B., Carmeli, Y., Falagas, M. E., Giske, C. G., Harbarth, S., Hindler, J. F., Kahlmeter, G., Olsson-Liljequist, B., et al. (2012) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2011.03570.x · Cited by 14,449
Antibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Kalil, A. C., Metersky, M. L., Klompas, M., Muscedere, J., Sweeney, D. A., Palmer, L. B., Napolitano, L. M., O'Grady, N. P., Bartlett, J. G., Carratalà, J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw353 · Cited by 3,892
Naghavi, M., Vollset, S. E., Ikuta, K. S., Swetschinski, L. R., Gray, A. P., Wool, E. E., Robles Aguilar, G., Mestrovic, T., Smith, G., Han, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01867-1 · Cited by 3,791
Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., Moran, G. J., Nicolle, L. E., Raz, R., Schaeffer, A. J., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq257 · Cited by 3,038
Updated Functional Classification of β-Lactamases
Bush, K., & Jacoby, G. A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-09 · Cited by 2,367
Jacoby, G. A. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00036-08 · Cited by 2,165
Lister, P. D., Wolter, D. J., & Hanson, N. D. (2009) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-09 · Cited by 1,789
Stenotrophomonas maltophilia: an Emerging Global Opportunistic Pathogen
Brooke, J. S. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00019-11 · Cited by 1,434
Research works printed but not linked: 10
- Clinical and Laboratory Standards Institute, 2023, M100: performance standards for antimicrobial susceptibility testing
- Sharara, 2019, Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by ESBL-producing organisms?, Clin Infect Dis, 71
- Centers for Disease Control and Prevention, 2015, Facility guidance for control of carbapenem-resistant Enterobacteriaceae (CRE): November 2015 update—CRE toolkit
- Chen, 2022, Efficacy and safety of ceftazidime-avibactam for the treatment of carbapenem-resistant enterobacterales bloodstream infection: a systematic review and meta-analysis, Microbiol Spectr, 10
- Shields, 2017, Emergence of ceftazidime-avibactam resistance due to plasmid-borne blaKPC-3 mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections, Antimicrob Agents Chemother, 61
- Li, 2022, Increased expression and amplification of blaKPC-2 contributes to resistance to ceftazidime/avibactam in a sequence type 11 carbapenem-resistant Klebsiella pneumoniae strain, Microbiol Spectr, 10
- Morrissey, 2020, In vitro activity of eravacycline against gram-negative bacilli isolated in clinical laboratories worldwide from 2013 to 2017, Antimicrob Agents Chemother, 64
- Karlowsky, 2020, In vitro activity of imipenem/relebactam and ceftolozane/tazobactam against clinical isolates of gram-negative bacilli with difficult-to-treat resistance and multidrug-resistant phenotypes—SMART United States 2015–2017, Clin Infect Dis, 72
- Skoglund, 2018, In vivo resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa arising by AmpC- and non-AmpC-mediated pathways, Case Rep Infect Dis, 2018
- Cheah, 2015, New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection, J Antimicrob Chemother, 70, 3291
Cited by
ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics
Miller, W. R., & Arias, C. A. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-024-01054-w · Cited by 862
“…(for which sulbactam is the active component against A. baumannii PBP3) is the current preferred backbone of therapy, with evidence of improved outcomes when used at a high dose (≥9 g per day of sulbactam) in combination with another active agent in mostly observational studies 180 .”
Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics
Wood, S. J., Kuzel, T. M., & Shafikhani, S. H. (2023) · Cells · doi:10.3390/cells12010199 · Cited by 254
Hypervirulent and carbapenem-resistant Klebsiella pneumoniae: A global public health threat
Lei, T.-Y., Liao, B.-B., Yang, L.-R., Wang, Y., & Chen, X.-B. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127839 · Cited by 174
Kaye, K. S., Belley, A. C., Barth, P., Lahlou, O., Knechtle, P., Motta, P., & Vélicitat, P. (2022) · JAMA · doi:10.1001/jama.2022.17034 · Cited by 158
Carmeli, Y., Cisneros, J. M., Paul, M., Daikos, G. L., Wang, M., Torre‐Cisneros, J., Singer, G., Titov, I., Gumenchuk, I., Zhao, Y., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00499-7 · Cited by 146
Wise, M. G. G., Karlowsky, J. A., Mohamed, N., Hermsen, E. D., Kamat, S., Townsend, A., Brink, A. J., Soriano, À., Paterson, D. L., Moore, L. S. P., et al. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.03.020 · Cited by 154
Schuetz, A. N., Ferrell, A., Hindler, J. A., Humphries, R. M., & Bobenchik, A. M. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.01623-23 · Cited by 132
Huston, J. M., Barie, P. S., Dellinger, E. P., Forrester, J. D., Duane, T. M., Tessier, J. M., Sawyer, R. G., Caínzos, M., Rasa, H. K., Chipman, J. G., et al. (2024) · Surgical Infections · doi:10.1089/sur.2024.137 · Cited by 132
“61 Anti-fungal therapy • We suggest against empiric anti-fungal therapy in lower risk patients (Grade 2-”
Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
Syed, Y. Y. (2021) · Drugs · doi:10.1007/s40265-021-01580-4 · Cited by 123
“Cefiderocol is approved for the treatment of adults with cUTIs (including pyelonephritis), HAP or VAP, caused by designated susceptible Gram-negative bacteria, in the USA [67] and for the treatment of infections caused by aerobic Gram-negative bacteria in adults with limited treatment options in the EU [68].”
BackgroundTherapeutic Options for Metallo-β-Lactamase-Producing Enterobacterales
Tan, X., Kim, H. S., Baugh, K., Huang, Y., Kadiyala, N., Wences, M., Singh, N., Wenzler, E., & Bulman, Z. P. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s246174 · Cited by 116
Soriano, À., Carmeli, Y., Omrani, A. S., Moore, L. S. P., Tawadrous, M., & Irani, P. M. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00507-6 · Cited by 113
Source control in emergency general surgery: WSES, GAIS, SIS-E, SIS-A guidelines
Coccolini, F., Sartelli, M., Sawyer, R., Rasa, K., Viaggi, B., Abu-Zidan, F., Soreide, K., Hardcastle, T., Gupta, D., Bendinelli, C., et al. (2023) · World Journal of Emergency Surgery · doi:10.1186/s13017-023-00509-4 · Cited by 99
Melchiorri, D., Rocke, T. P., Alm, R. A., Cameron, A. M., & Gigante, V. (2024) · The Lancet Microbe · doi:10.1016/j.lanmic.2024.100992 · Cited by 103
Marıno, A., Augello, E., Stracquadanio, S., Bellanca, C. M., Cosentino, F., Spampinato, S., Cantarella, G., Bernardini, R., Stefani, S., Cacopardo, B. S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25136814 · Cited by 97
“However, this approach often comes with a significant pharmacological burden and suboptimal efficacy [6].”
BackgroundShields, R. K., Abbo, L. M., Ackley, R., Aitken, S. L., Albrecht, B., Babiker, A., Burgoon, R., Cifuentes, R. O., Claeys, K. C., Curry, B. N., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(24)00648-0 · Cited by 95
Self-citationFalcone, M., Giordano, C., Leonildi, A., Galfo, V., Lepore, A., Suardi, L., Riccardi, N., Barnini, S., & Tiseo, G. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad725 · Cited by 87
Yehya, A., Ezzeddine, Z., Chakkour, M., Dhaini, Z., Saba, M. S. B., Saba, A. S. B., Nohra, L., Nassar, N. B., Yassine, M., Bahmad, H. F., et al. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1565965 · Cited by 90
Zhu, Y., Chen, J., Shen, H., Chen, Z., Yang, Q., Zhu, J., Li, X., Yang, Q., Zhao, F., Ji, J., et al. (2021) · mSystems · doi:10.1128/msystems.00787-21 · Cited by 80
The global burden of antimicrobial resistance – urinary tract infections
von Vietinghoff, S., Shevchuk, O., Dobrindt, U., Engel, D. R., Jorch, S. K., Kurts, C., Miethke, T., & Wagenlehner, F. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad233 · Cited by 89
Treatment of infections caused by carbapenem-resistant Acinetobacter baumannii
Zhang, S., Di, L., Qi, Y., Xiang, Q., & Wang, S. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1395260 · Cited by 86
Treatment Approaches for Carbapenem-Resistant Acinetobacter baumannii Infections
Iovleva, A., Fowler, V. G., & Doi, Y. (2024) · Drugs · doi:10.1007/s40265-024-02104-6 · Cited by 75
“An alternative dosing strategy has been proposed based on available population PK and animal data, where 6 to 9 g of sulbactam per day is administered as extended or continuous infusion, with the theoretical goal to saturate the PBP targets [131–134].”
Laboratory detection of carbapenemases among Gram-negative organisms
Simner, P. J., Pitout, J. D. D., & Dingle, T. C. (2024) · Clinical Microbiology Reviews · doi:10.1128/cmr.00054-22 · Cited by 73
Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations
Kubin, C. J., Garzia, C., & Uhlemann, A. (2025) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01063-24 · Cited by 73
Sartelli, M., Tascini, C., Coccolini, F., Dellai, F., Ansaloni, L., Antonelli, M. M., Bartoletti, M., Bassetti, M., Boncagni, F., Carlini, M., et al. (2024) · World Journal of Emergency Surgery · doi:10.1186/s13017-024-00551-w · Cited by 77
“…of America (IDSA) guidance suggest using eravacycline as an alternative option for the treatment of infections secondary to ESBL-producing and CPE (including KPC, metallo-beta-lactamases [MBLs], OXA-48 producing strains), except for the treatment of bloodstream or urinary tract infections [173].”
BackgroundCurrent and emerging strategies to curb antibiotic-resistant urinary tract infections
Simoni, A. A., Schwartz, L., Junquera, G. Y., Ching, C. B., & Spencer, J. D. (2024) · Nature Reviews Urology · doi:10.1038/s41585-024-00877-9 · Cited by 74
Alosaimy, S., Lagnf, A. M., Morrisette, T., Scipione, M. R., Zhao, J. J., Jorgensen, S. C. J., Mynatt, R. P., Carlson, T. J., Jo, J., Garey, K. W., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab371 · Cited by 61
Abdelmoneim, S. A., Ghazy, R. M., Sultan, E. A., Hassaan, M. A., & Mahgoub, M. A. (2024) · Scientific Reports · doi:10.1038/s41598-024-56254-4 · Cited by 67
Yuan, P., Dai, L.-T., Zhang, Q., Zhong, Y.-X., Liu, W.-T., Yang, L., & Chen, D. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.00008-24 · Cited by 65
Trends in empiric broad-Spectrum antibiotic use for suspected community-onset Sepsis in US hospitals
Rhee, C., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18923 · Cited by 58
Pierce, V., Bhowmick, T., & Simner, P. J. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.00074-22 · Cited by 58
Antimicrobial Treatment of Pseudomonas aeruginosa Severe Sepsis
Zakhour, J., Sharara, S. L., Hindy, J.-R., Haddad, S. F., & Kanj, S. S. (2022) · Antibiotics · doi:10.3390/antibiotics11101432 · Cited by 48
Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii
Karruli, A., Migliaccio, A., Pournaras, S., Durante‐Mangoni, E., & Zarrilli, R. (2023) · Antibiotics · doi:10.3390/antibiotics12121729 · Cited by 53
“Consistent with these data, the Infectious Disease Society of America (IDSA) recommended that FDC should be used with caution for CRAB infections and as part of a combination treatment regimen [70].”
ResultUpdated antimicrobial dosing recommendations for obese patients
Castro‐Balado, A., Varela-Rey, I., Mejuto, B., Mondelo‐García, C., Zarra‐Ferro, I., Rodríguez-Jato, T., & Fernández‐Ferreiro, A. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-23 · Cited by 60
McLeod, S. M., O’Donnell, J. P., Narayanan, N., Mills, J., & Kaye, K. S. (2024) · Future Microbiology · doi:10.2217/fmb-2023-0248 · Cited by 55
Li, Q., Zhou, X., Yang, R., Shen, X., Li, G., Zhang, C., Li, P., Li, S., Xie, J., & Yang, Y. M. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1376513 · Cited by 64
Metallo-beta-lactamases: mechanisms, treatment challenges, and future prospects
Zakhour, J., Ayoubi, L. W. E., & Kanj, S. S. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2311213 · Cited by 48
“As for A. baumannii , although no clear recommendations are made, and until further studies are published, cefiderocol seems to be active against CRAB including MBL producers and is an acceptable alternative if other first-line therapies are not effective [53].”
BackgroundInfluentialCost Analysis of New Antibiotics to Treat Multidrug-Resistant Bacterial Infections: Mind the Gap
Yahav, D., Shepshelovich, D., & Tau, N. (2021) · Infectious Diseases and Therapy · doi:10.1007/s40121-021-00412-y · Cited by 46
Souèges, S., Faure, E., Parize, P., Lanternier, F., Lécuyer, H., Huynh, A., Martin‐Blondel, G., Gaborit, B. J., Blot, M., Magallon, A., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106376 · Cited by 44
Gatti, M., Cosentino, F., Giannella, M., Viale, P., & Pea, F. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.107047 · Cited by 43
Treatment Strategies of Colistin Resistance Acinetobacter baumannii Infections
Papazachariou, A., Tziolos, N., Karakonstantis, S., Ιωάννου, Π., Samonis, G., & Kofteridis, D. P. (2024) · Antibiotics · doi:10.3390/antibiotics13050423 · Cited by 43
“Ampicillin/sulbactam is still recommended even in case of resistance to ampicillin/sulbactam, as defined based on CLSI breakpoints [56].”
BackgroundMethodInfluentialSerapide, F., Guastalegname, M., Gullì, S. P., Lionello, R., Bruni, A., Garofalo, E., Longhini, F., Trecarichi, E. M., & Russo, A. (2024) · Antibiotics · doi:10.3390/antibiotics13060506 · Cited by 43
Islam, M. M., Jung, D. E., Shin, W. S., & Oh, M. H. (2024) · Pathogens · doi:10.3390/pathogens13121049 · Cited by 45
Wenzler, E., Butler, D. A., Tan, X., Katsube, T., & Wajima, T. (2021) · Clinical Pharmacokinetics · doi:10.1007/s40262-021-01086-y · Cited by 42
Antibiotic Treatment of Infections Caused by AmpC-Producing Enterobacterales
Tebano, G., Zaghi, I., Cricca, M., & Cristini, F. (2024) · Pharmacy · doi:10.3390/pharmacy12050142 · Cited by 49
“Third-generation cephalosporins retain a role, together with non-beta-lactam options, for the treatment of non-invasive infections, such as uncomplicated urinary tract infections (UTIs) (Table 3) [32,41,76].”
BackgroundResultInfluentialTchesnokova, V. L., Larson, L., Basova, I., Sledneva, Y., Choudhury, D., Solyanik, T., Heng, J., Bonilla, T. C., Pham, S., Schartz, E. M., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00337-2 · Cited by 43
Shields, R. K., Dorazio, A. J., Tiseo, G., Squires, K. M., Leonildi, A., Giordano, C., Kline, E. G., Barnini, S., Iovleva, A., Griffith, M. P., et al. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae146 · Cited by 40
Warady, B. A., Same, R. G., Borzych–Dużałka, D., Neu, A. M., Mikati, I. E., Mustafa, R. A., Begin, B., Nourse, P. J., Bakkaloglu, S. A., Chadha, V., et al. (2024) · Peritoneal Dialysis International · doi:10.1177/08968608241274096 · Cited by 40
Grabein, B., Arhin, F. F., Daikos, G. L., Moore, L. S. P., Balaji, V., & Baillon-Plot, N. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-01044-8 · Cited by 40
Salleh, M. Z., Zuraina, N. M. N. N., Deris, Z. Z., & Mohamed, Z. (2025) · PeerJ · doi:10.7717/peerj.18986 · Cited by 45
Jain, M., Stitt, G. A., Son, L., & Enioutina, E. Y. (2023) · Microorganisms · doi:10.3390/microorganisms11102393 · Cited by 45
“However, carbapenems and non-β -lactam antibiotics remain active against ESBL-E organisms (Table 1 and [6]).”
BackgroundInfluentialHenriksen, A. S., Jeannot, K., Oliver, A., Perry, J. D., Pletz, M. W., Stefani, S., Morrissey, I., Longshaw, C. M., ARTEMIS Study Investigators, Willinger, B., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.03836-23 · Cited by 46
Boattini, M., Bianco, G., Llorente, L. I., Acero, L. A., Nunes, D., Seruca, M., Mendes, V. S., Almeida, A., Bastos, P. A. D., Rodríguez-Villodres, Á., et al. (2024) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2024.107115 · Cited by 38
Kharaghani, A. A., Harzandi, N., Khorsand, B., Rajabnia, M., Kharaghani, A. A., & Houri, H. (2023) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-023-00630-x · Cited by 43
Introducing new antibiotics for multidrug-resistant bacteria: obstacles and the way forward
Tängdén, T., Carrara, E., Hellou, M. M., Yahav, D., & Paul, M. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.09.025 · Cited by 37
A Systematic Literature Review of the Epidemiology of Complicated Urinary Tract Infection
Broughton, E. I., Bektas, M., Colosia, A. D., Kuper, K. M., Fernandez, M., Al-Taie, A., & Kotb, R. E. M. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01149-8 · Cited by 37
Chmielewska, S. J., Skłodowski, K., Depciuch, J., Deptuła, P., Piktel, E., Fiedoruk, K., Kot, P., Paprocka, P., Fortunka, K., Wollny, T., et al. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030425 · Cited by 38
Holger, D. J., Kebriaei, R., Morrisette, T., Lev, K. L., Alexander, J. L. R., & Rybak, M. J. (2021) · Antibiotics · doi:10.3390/antibiotics10050556 · Cited by 40
Das, S., Riccobene, T. A., Carrothers, T. J., Wright, J. G., Macpherson, M. P., Cristinacce, A., McFadyen, L., Xie, R., Luckey, A., & Raber, S. R. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03609-x · Cited by 36
Haidar, G., Kline, E. G., Kitsios, G. D., Wang, X., Kwak, E. J., Newbrough, A., Friday, K., Kramer, K. H., & Shields, R. K. (2024) · JAC-Antimicrobial Resistance · doi:10.1093/jacamr/dlae141 · Cited by 36
Treatment approaches for severe Stenotrophomonas maltophilia infections
Mojica, M. F., Bonomo, R. A., & van Duin, D. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000975 · Cited by 36
Self-citationReviewing novel treatment options for carbapenem-resistant Enterobacterales
Mackow, N., & van Duin, D. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2303028 · Cited by 39
Baltas, I., Patel, T. A., & Soares, A. (2024) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkae367 · Cited by 37
Boattini, M., Gaibani, P., Comini, S., Costa, C. S., Cavallo, R., Broccolo, F., & Bianco, G. (2025) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-025-05080-1 · Cited by 35
Corcione, S., Longo, B. M., Scabini, S., Pivetta, E. E., Curtoni, A., Shbaklo, N., Costa, C. S., & Rosa, F. G. D. (2024) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2024.06.010 · Cited by 34
Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections
Park, S. Y., Baek, Y. J., Kim, J. H., Seong, H., Kim, B., Kim, Y. C., Yoon, J. G., Heo, N., Moon, S. M., Kim, Y. A., et al. (2024) · Infection and Chemotherapy · doi:10.3947/ic.2024.0038 · Cited by 35
“…trimethoprim-sulfamethoxazole, nitrofurantoin, and single-dose aminoglycosides as the first-line therapy for CRE-induced cystitis, and the European guidelines recommend using one of the available drugs with established susceptibility based on the infective source for mild CRE infections [6, 63].”
BackgroundThe real crisis in antimicrobial resistance: failure to anticipate and respond
Bonomo, R. A., Perez, F., Hujer, A. M., Hujer, K. M., & Vila, A. J. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciad758 · Cited by 33
Self-citationTorres, A., Wible, M., Tawadrous, M., Irani, P. M., Stone, G. G., Quintana, A., Debabov, D. V., Burroughs, M., Bradford, P. A., & Kollef, M. H. (2023) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkad280 · Cited by 35
Heithoff, D. M., Barnes, L., V, Mahan, S. P., Fried, J., Fitzgibbons, L. N., House, J. K., & Mahan, M. J. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101023 · Cited by 32
Current Epidemiological Status and Antibiotic Resistance Profile of Serratia marcescens
Cosimato, I., Santella, B., Rufolo, S., Sabatini, P., Galdiero, M., Capunzo, M., Boccia, G., Folliero, V., & Franci, G. (2024) · Antibiotics · doi:10.3390/antibiotics13040323 · Cited by 38
“In recent years, however, the incidence of S. marcescens resistant to fluoroquinolones has increased due to the increased use of these drugs in the treatment of hospitalized patients [10].”
BackgroundChoi, S. J., & Kim, E. S. (2024) · Infection and Chemotherapy · doi:10.3947/ic.2024.0055 · Cited by 33
“In summary, colistin-based combination therapy, particularly colistin plus meropenem, is no longer recommended for CRAB infections [29, 57].”
BackgroundMethodInfluentialKizito, S. N., Migisha, R., Okello, P. E., Simbwa, B. N., Kabami, Z., Agaba, B., Zalwango, J. F., Naiga, H. N., Zalwango, M. G., Wanyana, M. W., et al. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09806-y · Cited by 39
Li, J., Wu, W., Wu, H., Huang, J., Li, Z., Wang, J., Zhou, Z., Wu, M., Wu, X., Zhao, Y., et al. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128049 · Cited by 32
Echegorry, M., Marchetti, P., Sanchez, C., Olivieri, L., Faccone, D. F., Martino, F., Badola, T. S., Ceriana, P., Rapoport, M., Lucero, C., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13121139 · Cited by 30
Kam, K. Q., Chen, T., Kadri, S. S., Lawandi, A., Yek, C., Walker, M., Warner, S., Fram, D., Chen, H.-C., Shappell, C. N., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciae591 · Cited by 29
Li, J., Wu, W., Wu, M., Zhou, Z., Wang, J., Qiu, M., Li, X., Ren, J., & Wu, X. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s455146 · Cited by 30
Nicola, F., Cejas, D., González-Espinosa, F., Relloso, S., Herrera, F., Bonvehí, P., Smayevsky, J., Figueroa-Espinosa, R. A., Gutkind, G., & Radice, M. A. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03733-22 · Cited by 30
Nanomedicine against biofilm infections: A roadmap of challenges and limitations
Blanco‐Cabra, N., Alcàcer‐Almansa, J., Admella, J., Arévalo‐Jaimes, B. V., & Torrents, E. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1944 · Cited by 31
Moeck, G., Gasink, L. B., Mendes, R. E., Woosley, L. N., Dorr, M., Chen, H., Wagenlehner, F., Henkel, T., & McGovern, P. C. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00236-24 · Cited by 30
Lai, C., Ma, Z., Zhang, J., Wang, J., Wang, J., Wu, Z., & Luo, Y. (2024) · Systematic Reviews · doi:10.1186/s13643-024-02695-x · Cited by 28
“These results have significant implications for clinical decision-making in the management of CRGNB infections, particularly in high-risk patient populations [92, 93].”
Vidal, P., Fernández, S. C., Fito, E. C., Carbajo, L. D. R., Fernández‐Ugidos, P., López-Ciudad, V. J., Olmo, J. N.-D., Rodríguez-Vázquez, A., & Varela, A. I. T. (2025) · Antibiotics · doi:10.3390/antibiotics14020178 · Cited by 32
“Extended infusions (3 h) of CFT-TAZ, CAZ-AVI, and cefiderocol are routinely recommended by clinical guidelines for treating severe infections with high bacterial burdens [45,233–235].”
Oliva, A., Liguori, L., Covino, S., Petrucci, F., Dezza, F. C., Curtolo, A., Savelloni, G., Comi, M., Sacco, F., Ceccarelli, G., et al. (2024) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-024-04833-8 · Cited by 28
Bamford, A., Masini, T., Williams, P. C. M., Sharland, M., Gigante, V., Dixit, D., Sati, H. F., Huttner, B. D., Nisar, Y. B., Cappello, B., et al. (2024) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(24)00048-8 · Cited by 30
Zhan, Y., Mao, W., Zhao, C., Lu, D., Chen, C., Hu, W., & Yang, Q. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09899-5 · Cited by 26
Rajer, F., Allander, L., Karlsson, P. A., & Sandegren, L. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00290-22 · Cited by 25
Soni, M., Kapoor, G. T., Perumal, N., & Chaurasia, D. (2023) · Cureus · doi:10.7759/cureus.39243 · Cited by 25
Pedro, D. M., Paulo, S. E., Santos, C., Fonseca, A. B., Melo‐Cristino, J., Pereira, Á. A., & Caneiras, C. S. G. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1347521 · Cited by 25
Aitken, S. L., Pierce, V., Pogue, J. M., Kline, E. G., Tverdek, F. P., & Shields, R. K. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciae229 · Cited by 24
Self-citationFeng, Y., Yang, Y., Hu, Y., Xiao, Y., Xie, Y., Wei, L., Wen, H., Zhang, L., McNally, A., & Zong, Z. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114602 · Cited by 24
Jin, S., Wang, W., Jiang, Y.-H., Yu, Y., & Wang, R. (2025) · Infection and Drug Resistance · doi:10.2147/idr.s502175 · Cited by 24
“138 The Infectious Diseases Society of America (IDSA) 136 recommends trimethoprim-sulfamethoxazole, ciprofloxacin, or levofloxacin as first-choice antibiotics for ESBL-producing Enterobacterales (ESBL-E) infections in the urinary tract, with alternatives like ertapenem or meropenem for resistant…”
Eid, R., Dabar, G., Hanna, L.-R., Saliba, G., Riachy, M. A., Choucair, J., & Saliba, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-90791-w · Cited by 24
“While MDR strains are resistant to multiple drugs but may still be susceptible to one or two classes of antibiotics, DTR strains have a more limited set of treatment options 2,3 .”
Méndez-Sotelo, B. J., Delgado-Beltrán, M., Hernández-Durán, M., Colín‐Castro, C. A., Esquivel-Bautista, J., Ortega-Oliva, S. A., Ortiz-Álvarez, J., García‐Contreras, R., Franco‐Cendejas, R., & López-Jácome, L. E. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298577 · Cited by 25
Halim, J., Carr, R. A., Fliorent, R., Jonnalagadda, K. S., Kurbonnazarova, M., Kaur, M., Millstein, I. D., & Carabetta, V. J. (2024) · Microorganisms · doi:10.3390/microorganisms12071353 · Cited by 24
“In support of this, in their recent 2023 guidelines for treatment of CRAB infections, The Infectious Disease Society of America (IDSA) suggests minocycline as the tetracycline drug of choice in treating CRAB infections [49].”
InfluentialZhuang, H.-H., Chen, Q., Wang, W. J., Qu, Q., Xu, W.-X., Hu, Q., Wu, X., Chen, Y., Wan, Q., Xu, T., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1413563 · Cited by 24
Fitzpatrick, M. A., & Nwafo, N. (2024) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2024.03.012 · Cited by 23
Klaiss-Luna, M. C., & Manrique-Moreno, M. (2022) · Membranes · doi:10.3390/membranes12050534 · Cited by 23
Cerón, S., Salem-Bango, Z., Contreras, D. A., Ranson, E. L., & Yang, S. (2023) · Microorganisms · doi:10.3390/microorganisms11071717 · Cited by 23
Henriksen, A. S., Arena, F., Attwood, M., Cantón, R., Gatermann, S. G., Naas, T., Morrissey, I., Longshaw, C. M., ARTEMIS Study Investigators, Willinger, B., et al. (2024) · Microbiology Spectrum · doi:10.1128/spectrum.04181-23 · Cited by 28
Tüzemen, N. Ü., Önal, U., Merdan, O., Akça, B., Ener, B., Özakın, C., & Akalın, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-67347-5 · Cited by 23
Clancy, C. J., Cornely, O. A., Marcella, S. W., Nguyen, S., Gozalo, L., & Cai, B. (2024) · Infection and Drug Resistance · doi:10.2147/idr.s475462 · Cited by 25
“36 Although guideline-recommended carbapenems and beta-lactam–beta-lactamase inhibitors had been utilized among patients with prior antimicrobial treatment, 37 escalation or switch to cefiderocol treatment was required in this patient population.”
MethodSelf-citationCarbonell, N., Oltra, M. R., & Clari, M. Á. (2024) · Antibiotics · doi:10.3390/antibiotics13070577 · Cited by 22
“The panel also changed the aztreonam regimen in terms of suggested antibiotics dosing from the previous publication [30,53].”
BackgroundInfluential
Metadata
- Authors
- Tamma, P. D., Aitken, S. L., Bonomo, R. A., Mathers, A. J., van Duin, D., & Clancy, C. J.
- Affiliations
- Johns Hopkins University (US)
- University of Michigan (US)
- University Hospitals of Cleveland (US)
- University of Virginia (US)
- Department of Medicine, University of North Carolina School of Medicine , Chapel Hill, North Carolina ,
- University of Pittsburgh (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-07-18
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W4384665204
- Cited by
- 740
- References
- 697
- Citations by year
- 2026: 134 · 2025: 159 · 2024: 335 · 2023: 84
- FWCI
- 60.82
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- AstraZeneca
- Infectious Diseases Society of America
- Case Western Reserve University
- Medicines Company
- Melinta Therapeutics
- Entasis Therapeutics
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID 2022)
- Universidade Federal do Rio Grande do Sul
- Shionogi
- Basilea Pharmaceutica
- Wockhardt
- National Institutes of Health
- Centers for Disease Control and Prevention
- Allergan
- Topics
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Infections and bacterial resistance
- Keywords
- antimicrobial resistance, gram-negative bacterial infection, extended-spectrum beta-lactamase, AmpC beta-lactamase, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, carbapenem-resistant Acinetobacter baumannii, Stenotrophomonas maltophilia, antimicrobial therapy, empirical treatment, oral therapy, treatment duration, pediatric infection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.